In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...
The company plans to begin using the instrument in its Burlington, North Carolina, lab in the first quarter of the year and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results